February 2024 FDA Recall Mesalamine by Sun Pharmaceutical Industries Inc
D-0350-2024 - Failed Dissolution Specifications

This Class II drug recall was voluntarily initiated by Sun Pharmaceutical Industries Inc on February 5, 2024 for the product Mesalamine. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0350-2024

Reason for Recall
Failed Dissolution Specifications: Out of specification for dissolution.
Initiated
02-05-2024
Reported
03-06-2024
Quantity
54,960 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
SUN PHARMACEUTICAL INDUSTRIES INC
Nationwide in the U.S.
Mesalamine Extended-Release Capsules, USP 500mg, Rx Only, 120 Capsules per bottle, Manufactured by: Sun Pharmaceutical Industries Limited, Mohali, INDIA, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 63304-089-13.

Batch or Lot Expiration Information

Lot# s: MHD0606A, MHD0612A, Exp. 04/30/2024; MHD0613A, MHD0652A, MHD0657A, MHD0672A, MHD0673A, Exp. 05/31/2024; MHD0767A, MHD0768A, MHD0769A, MHD0785A, MHD0799A, MHD0800A, MHD0801A, Exp. 06/30/2024; MHD0827A, MHD0828A, MHD0875A, MHD0876A, MHD0898A, MHD0901A, Exp. 07/31/2024; MHD1081A, MHD1082A, MHD1087A Exp. 09/30/2024.

Affected Packages Involved in this Recall